IMforte
IMforte produced the first maintenance treatment ever approved for extensive-stage small-cell lung cancer, adding lurbinectedin to the immunotherapy that continues after chemotherapy.
Randomised after four cycles of carboplatin-etoposide-atezolizumab without progression. OS 13.2 vs 10.6 months from randomisation (HR 0.73); PFS HR 0.54. FDA approval 2 October 2025. Presented ASCO 2025 plenary; Lancet 2025. Adds myelosuppression and fatigue.
- Median 13.2 vs 10.6 months with Lurbinectedin + atezolizumab compared with Atezolizumab; about 2.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 27 percent lower chance of the event at any given time (hazard ratio 0.73, likely range 0.57 to 0.95).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Median 5.4 vs 2.1 months with Lurbinectedin + atezolizumab compared with Atezolizumab; about 3.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 46 percent lower chance of the event at any given time (hazard ratio 0.54, likely range 0.43 to 0.67).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: First-line maintenance after induction chemo-immunotherapy in ES-SCLC: lurbinectedin + atezolizumab vs atezolizumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
483 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Lurbinectedin + atezolizumab | 242 | 13.2 months | 0.73 (0.57–0.95) | — | link |
| Atezolizumab | 241 | 10.6 months | ||||
| Progression-free survival (IRF)primary | Lurbinectedin + atezolizumab | — | 5.4 months | 0.54 (0.43–0.67) | — | — |
| Atezolizumab | — | 2.1 months |
Pages like this
not linked directly; found by shared links- TrialATLANTIS
Shares Lurbinectedin, Small-cell lung cancer.
- CompanyPharmaMar
Shares Lurbinectedin, Small-cell lung cancer.
- TrialDeLLphi-305
Shares Chemo-immunotherapy induction → maintenance intensification (SCLC), Small-cell lung cancer.
- TrialIDeate-Lung02
Shares Lurbinectedin, Small-cell lung cancer.
- TrialIMpower133
Shares Atezolizumab, Small-cell lung cancer.
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Atezolizumab, Small-cell lung cancer.
- ProductPlatinum + etoposide (EP / CE)
Shares Chemo-immunotherapy induction → maintenance intensification (SCLC), Small-cell lung cancer.
- CompanyJazz Pharmaceuticals
Shares Lurbinectedin, Small-cell lung cancer.